Conflict of Interest in Federal Grants: 2 CFR 200.112
Updated 15 official sources
Quick Answer: 2 CFR 200.112 (opens in a new tab) is two sentences long: "Federal agencies must establish conflict of interest policies for Federal awards.
Full answer and how we checked it
A recipient or subrecipient must disclose in writing any potential conflict of interest to the Federal agency or pass-through entity in accordance with the established Federal agency policies." Grantsights checked that text on eCFR on November 8, 2026, when Title 2 was current through November 5, 2026. If you're a recipient, the section itself sets no dollar threshold, form, or deadline; those come from the awarding agency's conflict of interest policy and your award terms. For purchases made with award funds, 2 CFR 200.318(c)(1) (opens in a new tab) adds a separate procurement rule: keep written standards of conduct, and bar any employee, officer, agent, or board member with a real or apparent conflict from selecting, awarding, or administering a contract. Under PHS/NIH rules (42 CFR 50, Subpart F), investigators must disclose financial interests exceeding $5,000 from any single entity. Institutions must review disclosures, develop management plans for identified conflicts, and report FCOIs to the funding agency before spending award funds.
Who this is for: grant compliance officers, principal investigators, sponsored research staff, nonprofit finance leaders, procurement staff, and executives responsible for federal grant conflict-of-interest policies.
Data note: Checked July 26, 2026 against current 2 CFR 200.112 (opens in a new tab), 2 CFR 200.318 (opens in a new tab), 42 CFR 50 Subpart F (opens in a new tab), and agency policy pages. Award terms and agency procedures control any additional disclosure deadlines.
In this guide
- What Official COI Guidance Doesn't Tell You
- Best Fit and Bad Fit Checklist for Federal Grant COI Controls
- Organizational COI vs. Individual COI: Two Different Problems
- PHS/NIH FCOI Requirements: The Most Detailed Framework
- NSF COI Policy: Institutional Flexibility
- Procurement COI Under 2 CFR 200.318
- How COI Requirements Differ by Agency
- The COI Review and Management Process
- Subrecipient COI Monitoring
- Consequences of Non-Disclosure
- Common COI Scenarios and How to Handle Them
- Related Guides
- Sources
Conflict of interest rules exist because federal research and program funding depends on objective decision-making. When a PI owns stock in a company that could benefit from their research outcomes, or when a grants manager's spouse works for a vendor being considered for a subcontract, the potential for bias is real, even if neither person would actually let it influence their judgment.
Federal agencies take COI seriously. Under 42 CFR 50 Subpart F (opens in a new tab), PHS-funded institutions must have policies that identify and manage financial conflicts before award funds are spent. The Uniform Guidance at 2 CFR 200.112 (opens in a new tab) requires disclosure of COI across all federal awards. And procurement-specific rules at 2 CFR 200.318 (opens in a new tab) address conflicts in purchasing decisions.
This guide covers all three types of COI in federal grants, the disclosure requirements by agency, how management plans work, and the consequences of getting it wrong.
According to 2 CFR Part 200, federal award recipients must disclose potential conflicts of interest in writing to the awarding agency or pass-through entity. According to NIH, PHS-funded institutions must identify, manage, and report financial conflicts of interest before spending funds. According to EPA, financial assistance recipients may need organizational conflict procedures that go beyond individual disclosure forms. According to NSF, institutions are responsible for maintaining and enforcing written conflict-of-interest policies.
According to 42 CFR 50.605, PHS institutions must report an identified FCOI before spending award funds and within 60 days when a new conflict is found during an active award. According to 2 CFR 200.318, procurement standards now cover conflicts involving employees, officers, agents, board members, immediate family members, partners, and organizations that employ or may employ those people. According to 2 CFR 200.113, credible evidence of a federal criminal-law violation involving fraud, conflict of interest, bribery, or gratuity violations triggers prompt disclosure duties.
Our analysis is that COI failures usually come from treating disclosure as an annual paperwork task rather than a project-control system. For example, one nonprofit can have a clean board recusal record and still fail a federal review if the procurement file does not show who selected the vendor, when the conflict was disclosed, and how the conflicted person was excluded before selection. The strongest organizations connect disclosure, procurement review, subrecipient monitoring, board governance, and award setup so a conflict is caught before money moves.
Source check, June 3, 2026: Official COI guidance lists disclosure duties, but it rarely tells applicants which file evidence will persuade a monitor. Grantsights flags a grant-funded COI as unresolved unless the file shows 4 public proof points: the interest was disclosed before the decision, the conflicted person was removed from the selection path, an independent reviewer made or validated the decision, and the award file ties that control to the relevant federal rule. The apply decision is to proceed when those proof points exist before funds move. The stop decision is to pause procurement, subaward selection, or investigator spending when the only evidence is an annual COI form. For example, a board member can recuse from a vote and still leave a federal finding if staff cannot show who screened vendors after the recusal.
What Official COI Guidance Doesn't Tell You
Official COI guidance tells you what the rule requires, but it rarely shows how evidence moves through the grant file. The practical issue is timing. A disclosure after a procurement decision may be too late, even when the final price is fair and the conflicted person did not vote. Reviewers want to see the control before the decision: a disclosure form, a recusal record, an independent reviewer, a source-selection note, and a grant-file memo tying those pieces to 2 CFR 200.112 or 2 CFR 200.318.
The second issue is that different agencies care about different proof. NIH focuses on investigator-level financial interests and research objectivity. FEMA, HUD, DOJ, and state pass-through agencies often focus on procurement files, board member influence, subrecipient selection, and vendor records. A single generic COI policy can pass a board governance review but still miss the federal grant evidence trail.
Looking for your next grant?
About once a week, we email a short list of open grant calls with real deadlines from different funders. It lists open calls only.
No spam. Unsubscribe anytime.
Best Fit and Bad Fit Checklist for Federal Grant COI Controls
Use this checklist to decide whether your current conflict-of-interest process is enough for a federal award.
| Situation | Best Fit Control | Bad Fit Signal |
|---|---|---|
| PHS-funded research with investigators, consultants, or key personnel | Annual and new-interest SFI disclosures, COI committee review, training, and management plans before spending funds | The organization has only a board COI form and no investigator-level process |
| Federal grant-funded procurement | Written standards under 2 CFR 200.318, pre-selection disclosure, recusal notes, independent selection records, and contract file evidence | The conflict is disclosed only after the vendor has already been selected |
| Nonprofit board member has a financial link to a vendor or subrecipient | Board recusal plus procurement-file documentation showing no informal influence | Board minutes show a recusal, but the grant file has no procurement review |
| Subrecipient performs grant-funded research or services | Subaward terms that specify which COI policy applies, reporting timelines, and prime-recipient review duties | The prime assumes the subrecipient has a compliant policy without checking |
| Organization discovers credible evidence of fraud, bribery, gratuity, or COI violation | Escalation to counsel, written agency disclosure analysis under 2 CFR 200.113, and file documentation | Leadership waits for a confirmed violation before preserving evidence or notifying the award owner |
If you are screening grant opportunities and compliance obligations at the same time, use the Grantsights grant database to identify federal programs, then confirm COI terms in the NOFO, award terms, and agency policy.
Organizational COI vs. Individual COI: Two Different Problems
Conflict of interest in federal grants comes in two fundamental forms, and they require different solutions.
Individual Financial Conflict of Interest
An individual COI exists when a person involved in the design, conduct, reporting, or administration of a federal award has a personal financial interest that could affect their objectivity. Common examples:
- A PI holds equity in a startup that's developing a product related to their federally funded research
- An investigator receives consulting payments from a company whose product they're studying
- A grants administrator's family member works for a vendor competing for a subaward
- A researcher holds a patent on a technology that their grant-funded work could validate
Individual COI is the focus of most agency-specific regulations, particularly the PHS/NIH FCOI rules. The concern is that financial interests will consciously or unconsciously bias how the person performs their grant-funded work.
Organizational Conflict of Interest
An organizational COI occurs when the grantee organization itself has financial relationships or structural characteristics that could compromise its objectivity. This includes:
- A nonprofit grantee that also provides consulting services to entities it's supposed to evaluate under the grant
- A research organization with financial ties to a company in the same field as its federally funded research
- A pass-through entity that awards subawards to its own affiliates
- An organization whose board members have financial interests in potential subrecipients
Organizational COI is addressed broadly in 2 CFR 200.112 (opens in a new tab), which requires that federal award recipients disclose in writing any potential conflicts of interest to the federal awarding agency. The EPA has developed detailed organizational COI policies (opens in a new tab) that go beyond the baseline Uniform Guidance requirements.
PHS/NIH FCOI Requirements: The Most Detailed Framework
The Public Health Service (PHS), which includes NIH, CDC, FDA, HRSA, AHRQ, and other HHS agencies, has the most prescriptive COI framework in federal grants. It's codified at 42 CFR 50 Subpart F (opens in a new tab) and supplemented by guidance from the NIH Office of Extramural Research (opens in a new tab).
Who Must Disclose
Every "Investigator" on a PHS-funded project must disclose their significant financial interests (SFIs). Under the regulation, an Investigator is defined broadly as the project director or PI and any other person who is responsible for the design, conduct, or reporting of research, regardless of their title or position. This typically includes:
- Principal investigators and co-PIs
- Senior/key personnel listed on the award
- Other personnel who make independent decisions about the research design, conduct, or reporting
- Consultants who meet the Investigator definition
What Requires Disclosure
Investigators must disclose SFIs related to their institutional responsibilities, including the SFIs of their spouse and dependent children. Under 42 CFR 50.603, significant financial interests include:
- Remuneration: Any payments from a single entity exceeding $5,000 in the 12 months prior to disclosure (salary, consulting fees, honoraria, paid authorship)
- Equity interests: For a publicly traded entity, equity counts toward the $5,000 threshold together with remuneration from that entity. For a non-publicly traded entity, any equity interest (stock, stock options, or other ownership) is an SFI regardless of value, under 42 CFR 50.603 (opens in a new tab). There's no percentage-ownership test.
- Intellectual property rights: Income from patents, copyrights, and royalties, or rights in such when related to institutional responsibilities
- Reimbursed or sponsored travel: Travel paid by an outside entity related to institutional responsibilities (must disclose purpose, sponsor, destination, and duration)
What's Excluded from Disclosure
The regulation excludes certain interests from disclosure requirements:
- Salary, royalties, or other payments from the institution itself
- Income from investment vehicles like mutual funds and retirement accounts where the investigator doesn't directly control investment decisions
- Income from seminars, lectures, or teaching at educational institutions
- Income from advisory committees or review panels for government agencies, institutions of higher education, academic teaching hospitals, medical centers, or research institutes affiliated with institutions of higher education
Disclosure Timeline
Initial disclosure must happen at the time of application for PHS-funded research. Disclosures must be updated:
- Annually: At minimum, during the period of the award
- Within 30 days: When a new SFI is obtained (e.g., a new consulting arrangement or stock purchase)
- Before spending funds: The institution must review disclosures and determine whether any FCOI exists before federal funds are expended
NSF COI Policy: Institutional Flexibility
NSF takes a different approach from NIH. Rather than prescribing specific disclosure thresholds, NSF requires each proposing organization (opens in a new tab) to maintain its own written, enforced COI policy.
Key NSF Requirements
- Organizations employing more than 50 persons must have a written policy on conflict of interest
- The policy must address conditions under which outside activities, relationships, or financial interests are proper or improper
- The policy must provide for advance notification and review of outside interests
- All conflicts must be managed, reduced, or eliminated before award funds are expended
- The Authorized Organizational Representative (AOR) certifies at proposal submission that the organization has an appropriate COI policy in place
How NSF Differs from NIH
| Requirement | NIH (42 CFR 50 Subpart F) | NSF |
|---|---|---|
| Disclosure thresholds | Over $5,000 (remuneration plus public equity), or any private-company equity | Defined by institutional policy |
| Reporting to agency | Required (FCOI reports via eRA Commons) | Not routinely required |
| Travel disclosure | Specific travel disclosure required | Per institutional policy |
| Public accessibility | FCOI information must be publicly accessible | Not required |
| Retrospective review | Required when FCOI not identified timely | Not specified |
| Investigator training | Required before engaging in research | Per institutional policy |
For researchers who receive funding from both NIH and NSF, the practical approach is to follow the more stringent PHS/NIH requirements across all activities. Most university COI policies are designed to meet the PHS standard since it's the most prescriptive.
Procurement COI Under 2 CFR 200.318
Beyond research-related conflicts, the Uniform Guidance addresses conflicts of interest in procurement. This applies to every federal grant recipient, not just research institutions. Under 2 CFR 200.318(c) (opens in a new tab), organizations must maintain written standards of conduct covering conflicts of interest for employees engaged in the selection, award, and administration of contracts.
What the Procurement COI Rules Require
Your organization must have standards that address situations where any of the following people have a financial or other interest in a firm selected for a contract:
- Officers, employees, or agents of the organization
- Members of their immediate families
- Their partners
- Organizations that employ or are about to employ any of the above
These standards must also include provisions for organizational conflicts of interest, meaning situations where the non-federal entity is unable or appears unable to be impartial because of relationships with a parent company, affiliate, or subsidiary.
Practical Examples
- A grants administrator whose brother owns the IT company being considered for a grant-funded contract has a procurement COI and must recuse themselves from the selection process
- An organization that's both a grantee and a vendor to other grantees in the same program has an organizational procurement COI
- A board member whose company supplies office equipment to the organization shouldn't participate in decisions about purchasing equipment with grant funds
Penalties for procurement COI violations include questioned costs, repayment of funds, and potential suspension or debarment. For more on procurement rules, see our procurement standards guide.
How COI Requirements Differ by Agency
While 2 CFR 200.112 sets the baseline for all federal agencies, several agencies have adopted more specific COI policies in recent years.
Department of Energy (DOE)
DOE has implemented an interim conflict of interest policy (opens in a new tab) that goes beyond the Uniform Guidance baseline. It requires recipients to have written COI policies that cover both organizational and individual conflicts, and it includes specific disclosure requirements.
Environmental Protection Agency (EPA) and Health Resources and Services Administration (HRSA)
EPA and HRSA may impose additional financial-assistance conflict requirements through current agency policy, funding notices, and award terms. Confirm the live agency policy and award conditions for the applicable disclosure route and deadline rather than carrying a deadline from a prior policy version.
Department of Justice (DOJ)
The DOJ Office of Justice Programs (opens in a new tab) requires grantees to disclose COI related to any organizational relationships, and it specifically addresses conflicts that arise in subgranting and procurement.
Key Takeaway
Always check your specific funding announcement and agency terms and conditions for COI requirements. The agency-specific policy may be more restrictive than the Uniform Guidance baseline, and you're responsible for following whichever standard is stricter.
The COI Review and Management Process
When a disclosure identifies a potential conflict, the institution's COI review process determines whether an actual conflict exists and, if so, how to manage it.
Institutional COI Committee
Most organizations that receive federal research funding have a standing COI committee (sometimes called a conflict of interest or conflict of commitment committee). This committee:
- Reviews all investigator disclosures
- Determines whether disclosed interests constitute an FCOI
- Develops management plans for identified conflicts
- Monitors compliance with management plans
- Conducts retrospective reviews when COI wasn't identified in a timely manner
What Goes Into a Management Plan
According to 42 CFR 50.605 (opens in a new tab) and NIH FCOI guidance (opens in a new tab), the FCOI report must describe these key elements of the management plan:
- Role definition: A clear description of the conflicted investigator's role and responsibilities on the project
- Conditions and restrictions: Specific limitations on the investigator's involvement (e.g., excluded from certain data analysis, barred from making procurement decisions related to the conflicting entity)
- Safeguards: Measures to protect research objectivity, such as blinding protocols or independent data verification
- Investigator agreement: Written confirmation that the investigator understands and agrees to the management plan terms
- Monitoring procedures: How and when compliance with the plan will be verified
The regulation lists appointing an independent monitor, who can protect the design, conduct, and reporting of the research from bias, as one example of a condition a plan may impose.
Common Management Strategies
- Disclosure in publications and presentations: Requiring the investigator to disclose their financial interest in all public communications about the research
- Modification of research plan: Adjusting the investigator's role to remove decision points where bias could influence outcomes
- Independent oversight: Assigning an independent researcher to oversee data collection or analysis
- Divestiture: Requiring the investigator to sell their equity interest in the conflicting entity
- Recusal: Removing the investigator from specific aspects of the project entirely
Subrecipient COI Monitoring
If your organization passes federal funds to subrecipients, you're responsible for ensuring their investigators comply with applicable COI requirements. This obligation comes from both 2 CFR 200.332 (requirements for pass-through entities) and agency-specific regulations.
How Subrecipient COI Works Under PHS Rules
For PHS-funded awards, the prime recipient must enter into a written agreement with each subrecipient that establishes:
- Whether the prime recipient's or the subrecipient's COI policy will apply
- Disclosure timelines and reporting requirements
- How identified FCOIs will be reported to the prime recipient (and then to NIH)
If the subrecipient's COI policy will apply, it must comply with 42 CFR 50 Subpart F. If the subrecipient doesn't have a compliant policy, the prime recipient's policy must apply.
The prime recipient institution is responsible for reporting all identified FCOIs for subrecipient investigators to NIH through the eRA Commons FCOI Module, according to NIH Grants Policy Statement section 4.1.10 (opens in a new tab).
Practical Steps for Subrecipient COI Monitoring
- Include COI requirements in your subaward agreement template
- Verify that the subrecipient has a compliant COI policy (or agree that yours will apply)
- Establish clear timelines for subrecipient FCOI disclosures
- Document your monitoring procedures
- Ensure subrecipient investigator FCOIs are reported to the funding agency through your institution
For more on managing subawards, see our subaward guide.
Consequences of Non-Disclosure
Failing to disclose a conflict of interest, or failing to manage one properly, can trigger consequences at multiple levels.
Institutional Consequences
- Award suspension or termination: The agency can suspend or terminate the award
- Return of funds: The institution may be required to repay funds expended during the period of non-compliance
- Increased monitoring: Additional reporting requirements and oversight on current and future awards
- Debarment: In severe cases, the organization can be debarred from receiving future federal awards
- Audit findings: Organizations spending $1 million or more in federal awards in a fiscal year get a Single Audit, where weak conflict-of-interest and procurement controls can be reported as findings
Individual Consequences
- Removal from the project: The investigator may be removed from the grant-funded research
- Institutional disciplinary action: University or organizational sanctions, up to termination
- OIG referral: Intentional non-disclosure can be referred to the Office of Inspector General for investigation
- False Claims Act liability: If non-disclosure is connected to obtaining or retaining federal funds through false certifications, it can trigger FCA penalties. For more on FCA liability, see our grant fraud and False Claims Act guide.
NIH-Specific Consequences: Retrospective Review
When NIH identifies a previously undisclosed FCOI, the regulation requires the institution to conduct a retrospective review to determine whether the conflict biased the design, conduct, or reporting of the research. If bias is found, the institution must notify NIH and submit a mitigation report describing the impact and steps taken to address it.
This retrospective review requirement makes timely disclosure especially important for PHS-funded research. Discovering an undisclosed conflict years into a project triggers a complex, resource-intensive review process that can call the integrity of the entire body of research into question.
Common COI Scenarios and How to Handle Them
Scenario 1: PI Consults for a Company in Their Research Area
A PI receives $15,000 annually in consulting fees from a pharmaceutical company. Their NIH-funded grant involves studying a drug class that includes the company's products.
Required action: The PI must disclose the consulting income as an SFI (it exceeds the $5,000 threshold). The COI committee reviews whether the consulting relationship could bias the research. A management plan might include independent data monitoring, disclosure in all publications, and restrictions on the PI's involvement in data analysis related to the company's specific products.
Scenario 2: Investigator's Spouse Works for a Potential Vendor
An investigator's spouse is a sales manager at a laboratory equipment company. The grant budget includes $40,000 for equipment purchases.
Required action: The investigator should disclose the relationship under the institution's COI policy. For procurement purposes, the investigator must recuse themselves from any purchasing decisions involving the spouse's employer, per 2 CFR 200.318 (opens in a new tab). The procurement file should document that someone without a conflict made the vendor selection.
Scenario 3: Organization Has Equity in a Startup
A university holds equity in a startup founded by one of its faculty members. The faculty member submits an NIH grant to study a technology that the startup is commercializing.
Required action: This involves both individual and organizational COI. The faculty member's equity interest must be disclosed as an SFI. The university's institutional interest must be disclosed under 2 CFR 200.112. The COI committee needs to evaluate both levels of conflict and may need to implement management measures at both the investigator and institutional level.
Scenario 4: Board Member's Organization Seeks a Subaward
A nonprofit grantee's board member also serves as executive director of another organization that's being considered for a subaward under the grant.
Required action: The board member has a clear COI and must recuse themselves from all decisions related to the subaward selection and administration. The conflict should be disclosed to the federal awarding agency. The selection process must be documented to show that the subaward was awarded on merit without the conflicted board member's influence.
Related Guides
The 2024 2 CFR 200 Change That Added Board Members to Your COI Exposure
The 2024 revision to 2 CFR 200 introduced a change that many organizations haven't caught yet. The October 2024 update to 2 CFR 200.318(c) explicitly added board members to the list of individuals whose financial interests can create a procurement conflict of interest for grant recipients. Before October 2024, the regulation covered employees, officers, and agents. Board members were addressed in organizational COI policy guidance, but weren't specifically named in the procurement standards provision. That distinction mattered because many smaller nonprofits treated their board member conflicts as a governance issue handled through their bylaws rather than a federal grant compliance issue requiring formal disclosure and documentation.
Take a nonprofit with a board member who is also a principal in a construction firm. Under the pre-2024 framework, recusal from the relevant board votes, documented in board minutes, was often sufficient. Under the October 2024 revision, the organization is also now required to maintain written standards of conduct that explicitly cover board members in procurement decisions, disclose the relationship to the federal awarding agency under 2 CFR 200.112, and document that the board member didn't exert informal influence over the vendor selection. The recusal vote alone isn't enough anymore.
The second change from the 2024 revision that catches organizations off guard: the new credible evidence disclosure requirement. Under 2 CFR 200.113 as revised, recipients must promptly disclose when they have credible evidence of violations of federal criminal law involving fraud, conflict of interest, bribery, or gratuity violations. The key word is "credible evidence," not "confirmed violation." If your executive director discovers that a program manager has a financial relationship with a vendor being considered for a subcontract, and the program manager didn't disclose it, you now have an obligation to report that to the federal awarding agency, not just handle it internally. Organizations that don't have a documented internal whistleblower and reporting process are exposed on this requirement.
The practical problem: many nonprofits don't have COI policies that distinguish between personal financial conflicts under the PHS/NIH framework and procurement conflicts under 2 CFR 200. They have one policy that does everything. That single policy often fails to address the specific documentation requirements for procurement COI: who made the decision, what alternatives were considered, who was excluded from the selection process, and how the documentation was preserved. NIH cares primarily about the research objectivity framework. FEMA, HUD, and DOJ auditors care primarily about the procurement documentation. If you try to use a single policy to satisfy both, it often doesn't fully satisfy either.
There's a timing issue that organizations consistently underestimate: COI disclosures for procurement have to happen before the procurement decision, not after it. A disclosure made in the board meeting that ratifies a contract, rather than before the vendor is selected, can be treated as a procurement violation at a federal monitoring visit. Your COI policy needs to specify a pre-selection review step, not just a disclosure step.
The COI Policy Many Nonprofits Don't Have (Until the Auditor Asks)
The requirement is written plainly in 2 CFR 200.318(c)(1): organizations receiving federal funds must maintain written standards of conduct covering conflicts of interest. The regulation specifies that the policy must address situations where an employee, officer, or agent of the organization has a financial or other interest in the outcome of a procurement decision or grant-funded activity. Despite the clarity of the requirement, many small nonprofits either don't have a conflict of interest policy at all or have a generic one-page document downloaded from a template site that doesn't address the specific provisions the regulation requires. The gap between what organizations think they have covered and what a federal auditor or monitoring visit will actually examine is significant.
A short policy about board members disclosing conflicts, with no defined recusal procedure, no process for documenting the disclosure, and no mechanism for ensuring the conflicted party does not participate in the award decision, can fail a routine monitoring visit.
A functional COI policy needs to cover two distinct categories: organizational conflicts, where the entity itself benefits from a decision, and personal conflicts, where an individual within the organization benefits. The policy should specify how conflicts are identified, how they are disclosed, who reviews the disclosure, what actions are required (recusal, divestiture, or management plan), and how the decision is documented. Writing this policy takes a few hours. Not having it when an auditor asks can cost months of program delays and jeopardize future funding.
Sources
- 42 CFR Part 50 Subpart F - Promoting Objectivity in Research (opens in a new tab)
- Financial Conflict of Interest - NIH Grants & Funding (opens in a new tab)
- NIH Grants Policy Statement Section 4.1.10 (opens in a new tab)
- Conflicts of Interest - NSF Policies (opens in a new tab)
- 2 CFR 200.112 - Conflict of Interest (opens in a new tab)
- Conflict of Interest Policy - HRSA (opens in a new tab)
Next steps
Related federal grant compliance rules
These next pages help you move from research into a specific grant choice.
Procurement rules
Check vendor selection, written standards, board-member conflicts, and contract file proof.
Compliance guide
Use when COI duties need to be tied to award terms, reporting, and controls.
Subrecipients
Check which COI policy applies and what the prime must collect from subrecipients.
Fraud risk
Use when credible evidence, disclosure, or False Claims Act exposure may be involved.
Frequently Asked Questions
What is a conflict of interest in federal grants?
A conflict of interest in federal grants occurs when an individual's personal financial interests or relationships could compromise, or appear to compromise, their professional judgment in the design, conduct, reporting, or administration of a federally funded project. COI in grants falls into three categories: individual financial COI (a researcher owns stock in a company that could benefit from their grant-funded research), organizational COI (the grantee organization has financial ties that could bias its work), and procurement COI (someone involved in purchasing decisions has a financial interest in a potential vendor). Federal regulations at 2 CFR 200.112 and agency-specific rules like 42 CFR 50 Subpart F establish disclosure and management requirements.
What do PHS/NIH investigators have to disclose for FCOI?
Under 42 CFR 50 Subpart F, investigators on PHS-funded research (which includes NIH, CDC, FDA, HRSA, and other HHS agencies) must disclose all significant financial interests (SFIs) related to their institutional responsibilities. SFIs include, for a publicly traded entity, remuneration in the prior 12 months plus equity that together exceed $5,000; for a non-publicly traded entity, remuneration over $5,000 in the prior 12 months or any equity interest at all; and intellectual property rights and interests (patents, copyrights, royalties). Investigators must also disclose reimbursed or sponsored travel related to their institutional responsibilities, unless it comes from a federal, state, or local government agency, an institution of higher education, or certain other exempt entities.
What is a COI management plan and what does it include?
A COI management plan is a formal document that outlines the conditions under which a research project can proceed despite an identified financial conflict of interest. Under 42 CFR 50.605, the FCOI report must describe the plan's key elements: the conflicted investigator's role and principal duties, the plan's conditions, how the plan safeguards research objectivity, confirmation of the investigator's agreement, and how compliance will be monitored. Appointing an independent monitor is one possible condition, not a required element of every plan. Management plans are reviewed and approved by the institution's COI committee and must be reported to the funding agency.
How do COI requirements differ between NSF and NIH?
NSF and NIH both require institutions to maintain COI policies, but their approaches differ. NIH follows 42 CFR 50 Subpart F, which requires investigators to disclose specific financial interests above defined thresholds ($5,000 for remuneration, or remuneration plus publicly traded equity, and any equity in a non-publicly traded entity) and mandates institutional review before expenditure of funds. NSF requires each organization employing more than 50 persons to maintain a written, enforced COI policy, but it gives institutions more flexibility in defining the specifics. NSF's focus is on the institutional policy and its enforcement, while NIH prescribes detailed disclosure thresholds, reporting timelines, and management plan requirements. NSF does not require routine FCOI reporting to the agency, while NIH requires initial and annual FCOI reports through eRA Commons.
What are the consequences of failing to disclose a conflict of interest?
Failing to disclose a conflict of interest can trigger a range of consequences depending on severity and intent. At the institutional level, consequences include suspension or termination of the award, requirement to return funds, increased monitoring conditions, and potential debarment from future federal funding. For individual investigators, consequences include removal from the project, institutional disciplinary action, and potential referral to the Office of Inspector General if the non-disclosure appears intentional. NIH can require a retrospective review of the research to determine whether the undisclosed COI biased the design, conduct, or reporting of the work. If the retrospective review finds bias, the institution must notify NIH and submit a mitigation report.
Last updated October 11, 2026. Corrected October 9, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
2 CFR 200.1 Definitions: MTDC, Equipment, Thresholds
2 CFR 200.1 defines Uniform Guidance terms: MTDC counts the first $50,000 of each subaward, equipment starts at $10,000, micro-purchases run to $15,000.
2 CFR 200.404 Reasonable Costs: 5-Factor Test
Use the 5-factor 2 CFR 200.404 reasonable costs test, document price and policy evidence, and stop a federal grant charge when one factor is unresolved.
Cost Allocation Plan for Grants: 2 CFR 200 Guide
A cost allocation plan distributes shared costs across 2+ funding sources using 5 approved methods. Step-by-step guide with examples.
Grant Cost Sharing & Matching Requirements Guide
Many federal grants set a fixed match, such as 20% or 25%. Learn in-kind valuation, documentation rules, and 7 common matching pitfalls under 2 CFR 200.
Debarment & Suspension in Federal Grants Guide
Federal debarment and suspension under 2 CFR 180: SAM.gov exclusions, the $25,000 covered-contract rule, 30-day response, scope, and reinstatement.
Federal Grant Budget Categories Explained (2026 Guide)
Federal grants use 9 budget categories under 2 CFR 200. Learn the $10,000 equipment threshold and MTDC rules to avoid costly errors.